海外の治験の状況「%E8%84%B3%E5%8D%92%E4%B8%AD」での検索結果
32件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 国名
- 登録日
Authorised
- A 24-week, double-blind, double-dummy, randomized, parallel-group study to investigate the effects of rosiglitazone (extended release tablets), donepezil, and placebo as monotherapy on cognition and overall clinical response in APOE e4-stratified subjects with mild to moderate Alzheimer’s disease. (REFLECT-1)
- Mild to Moderate Alzheimer's Disease MedDRA version: 8.1 Level: LLT Classification code 10001896 Term: Alzheimer's disease
- Austria, Bulgaria, Estonia, Germany, Greece, Hungary, United Kingdom
- 2006-11-23
Authorised
- An Efficacy and Safety Trial of MK-8931 in Mild to Moderate AD (EPOCH)
- mild to moderate Alzheimer's Disease MedDRA version: 15.0 Level: LLT Classification code 10001896 Term: Alzheimer's disease System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
- Argentina, Australia, Austria, Belgium, Brazil, Canada, Czech Republic, Denmark, France, Germany, Hungary, Italy, Japan, Korea, Republic of, Netherlands, New Zealand, Portugal, Spain, Turkey, United Kingdom, United States
- 2012-10-02
Authorised
- To evaluate the efficacy and safety of CNP520 in participants at risk for the onset of clinical symptoms of Alzheimer’s Disease (AD)
- Alzheimer's disease MedDRA version: 19.1 Level: LLT Classification code 10001896 Term: Alzheimer's disease System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
- Argentina, Austria, Belgium, Canada, Chile, China, Finland, France, Germany, Hong Kong, Iceland, Israel, Italy, Japan, Korea, Republic of, Mexico, Netherlands, Portugal, Singapore, South Africa, Spain, Taiwan, United Kingdom, United States
- 2017-03-31
Authorised
- The efficacy and safety of a daily oral administration of S06911 (strontium ranelate 2g/vitamin D3 1000 IU fixed combination) on vitamin D insufficiency in the treatment of osteoporotic postmenopausal women and men. A prospective, international phase III study with a 6-month double-blind period to assess the efficacy and safety of a daily oral administration of S06911 versus S12911 (strontium ranelate 2g) and a 6-month open-labelled extension for a subgroup of patients to assess safety of a daily oral administration of S06911.
- Osteoporotic men and postmenauposal women MedDRA version: 12.0 Level: LLT Classification code 10031283 Term: Osteoporosis fracture MedDRA version: 12.0 Level: LLT Classification code 10031285 Term: Osteoporosis postmenopausal
- Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Hungary, Poland, Slovakia, Spain, United Kingdom
- 2009-10-26
Authorised
- This is a study to help understand how Baricitinib compares to placebo (a tablet that does not contain any active medicine) in adults with moderate to severe atopic dermatitis, also known as atopic eczema
- Atopic Dermatitis MedDRA version: 20.0 Level: LLT Classification code 10003639 Term: Atopic dermatitis System Organ Class: 100000004858 ;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
- Argentina, Australia, Austria, Hungary, Israel, Japan, Korea, Republic of, Poland, Spain, Switzerland
- 2017-10-05
Authorised
- A Safety and Efficacy Study for Alzheimer's Disease (Prodromal AD)
- prodromal Alzheimer's Disease MedDRA version: 16.0 Level: HLT Classification code 10001897 Term: Alzheimer's disease (incl subtypes) System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
- Argentina, Australia, Austria, Belgium, Brazil, Canada, Czech Republic, Finland, France, Germany, Italy, Japan, Netherlands, New Zealand, Norway, South Africa, Spain, Switzerland, United Kingdom, United States
- 2013-09-17
Authorised
- A study to help understand how Baricitinib in Combination with Topical Corticosteroids compares to placebo (a tablet that does not contain any active medicine) in patients with moderate to severe atopic dermatitis, also named atopic eczema
- Atopic Dermatitis MedDRA version: 20.0 Level: LLT Classification code 10003639 Term: Atopic dermatitis System Organ Class: 100000004858 ;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
- Argentina, Australia, Austria, Germany, Italy, Japan, Korea, Republic of, Poland, Spain, Taiwan
- 2018-09-26
Authorised
- A study to help understand how Baricitinib in Combination with Topical Corticosteroids compares to placebo (a tablet that does not contain any active medicine) in patients with moderate to severe atopic dermatitis, also named atopic eczema
- Atopic Dermatitis MedDRA version: 20.0 Level: LLT Classification code 10003639 Term: Atopic dermatitis System Organ Class: 100000004858 ;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
- Argentina, Australia, Austria, Germany, Italy, Japan, Korea, Republic of, Poland, Spain, Taiwan
- 2018-08-31
Authorised
- This is a long term extention study in patients with Atopic Dermatitis, also named eczema, that helps to understand how Baricitinib works BREEZE-AD1
- Atopic Dermatitis MedDRA version: 20.0 Level: LLT Classification code 10003639 Term: Atopic dermatitis System Organ Class: 100000004858 ;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
- Argentina, Australia, Austria, Czech Republic, Denmark, France, Germany, Hungary, India, Israel, Italy, Japan, Korea, Republic of, Mexico, Poland, Russian Federation, Slovenia, Spain, Switzerland, Taiwan
- 2017-09-22
Authorised
- An exploratory study to investigate the extent to which Dupilumab becomes available to the body as well as Its actions and effects in the liquid found between the skin cells of atopic dermatitis patients
- Atopic Dermatitis;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
- Austria
- 2018-09-28